Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

As the first cardiovascular (CV) outcome trial of a glucose-lowering agent to demonstrate a reduction in the risk of CV events in patients with type 2 diabetes mellitus (T2DM), the EMPAgliflozin Removal of Excess Glucose: Cardiovascular OUTCOME Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavaiola, Tricia Santos, Pettus, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905845/
https://www.ncbi.nlm.nih.gov/pubmed/29695924
http://dx.doi.org/10.2147/DMSO.S154602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905845/
https://www.ncbi.nlm.nih.gov/pubmed/29695924
http://dx.doi.org/10.2147/DMSO.S154602

Ejemplares similares